KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.

Thierry Facon, Philippe Moreau, Katja Weisel, Hartmut Goldschmidt, Saad Z Usmani, Ajai Chari, Torben Plesner, Robert Z Orlowski, Nizar Bahlis, Supratik Basu, Cyrille Hulin, Hang Quach, Michael O'Dwyer, Aurore Perrot, Caroline Jacquet, Christopher P Venner, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Gordon Cook, George Wang, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Shaji K Kumar

Leukemia 39(4) 942-950

PMID40016302
PMCIDPMC11976258
DOI10.1038/s41375-024-02505-2
发表日期2025-02-27
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

In the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and safety from MAIA (median follow-up, 64.5 months), including a subgroup analysis by patient age (<70, ≥70 to <75, ≥75, and ≥80 years). Overall, 737 transplant-ineligible patients with NDMM were randomized 1:1 to D-Rd or Rd. The primary endpoint, PFS, was improved with D-Rd versus Rd (median, 61.9 vs 34.4 months; hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.45-0.67; P < 0.0001). Median OS was not reached in the D-Rd group versus 65.5 months in the Rd group (HR, 0.66; 95% CI, 0.53-0.83; P = 0.0003); estimated 60-month OS rates were 66.6% and 53.6%, respectively. D-Rd achieved higher rates of complete response or better (≥CR; 51.1% vs 30.1%), minimal residual disease (MRD) negativity (32.1% vs 11.1%), and sustained MRD negativity (≥18 months: 16.8% vs 3.3%) versus Rd (all P < 0.0001). D-Rd demonstrated clinically meaningful efficacy benefits across age groups. No new safety concerns were observed. Updated results (median follow-up, >5 years) continue to support frontline use of D-Rd in transplant-ineligible patients with NDMM.

KM 提取结果

2 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 1

Fig. 1. PFS and OS in the ITT population. Kaplan–Meier estimates of ( A ) PFS and ( B ) OS in the ITT population. PFS progression-free survival, OS overall survival, ITT intent-to-treat, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, HR hazard ratio, CI confidence interval, NR not reached.

A

PFS

Fig. 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

Fig. 1 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

Fig. 2

Fig. 2. PFS and OS by age subgroup. Kaplan–Meier estimates of ( A ) PFS in patients aged <70 years, ≥70 to <75 years, and ≥75 years; ( B ) PFS in patients aged ≥80 years; ( C ) OS in patients aged <70 years, ≥70 to <75 years, and ≥75 years; and ( D ) OS in patients aged ≥80 years. PFS progression-free survival, OS overall survival, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, HR hazard ratio, CI confidence interval, NR not reached.

A

PFS

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 6 条 已提取 6 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
C

OS

Fig. 2 · Panel C

quality_warning 待 EXE 对齐 预期 6 条 已提取 5 条

Panel C 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 6 条,实际恢复 5 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

OS

Fig. 2 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 3Fig. 3. Cumulative best response rates of ≥CR and MRD negativity over time in the ITT population. A Cumulative ≥CR and ( B ) MRD-negativity rates by 12, 18, 24, 30, 36, 48, and 60 months in the ITT population. CR complete response, MRD minimal residual disease, ITT intent-to-treat, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone.
非 KM Figure
Fig. 4Fig. 4. Response rates over time in the ITT population. Response rates by 6, 12, 18, 24, and 30 months in the ITT population. ITT intent-to-treat, ORR overall response rate, CR complete response, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, PR partial response, VGPR very good partial response, sCR stringent complete response.
非 KM Figure